Abstract | BACKGROUND: Before renal transplantation complex abnormalities of bone metabolism exist and lead to increased risk for fracture after transplantation. This study was conducted to assess the evidence available to guide targeted treatment to reduce bone disease in transplant recipients. METHODS: The Cochrane CENTRAL Registry, MEDLINE, and EMBASE were searched for randomized trials of interventions for bone disease after renal transplantation. Data were extracted on fracture, bone mineral density (BMD) by means of dual-energy X-ray absorptiometry, acute graft rejection, and adverse events. Analysis was performed with a random-effects model, and all results are expressed as relative risk with 95% confidence intervals (CIs). RESULTS: Twenty-three eligible trials (1,209 patients) were identified. No trial found a reduction in risk for fracture. Bisphosphonates (7 trials; 268 patients; weighted mean difference [WMD], 7.66; 95% CI, 4.82 to 10.50), vitamin D analogues (2 trials; 51 patients; WMD, 6.13; 95% CI, 4.97 to 7.29), and calcitonin (1 trial; 31 patients; WMD, 5.00; 95% CI, 0.88 to 9.12) favorably affected the percentage of change in BMD at the lumbar spine compared with no treatment. Bisphosphonates (4 trials; 149 patients; WMD, 7.18; 95% CI, 6.22 to 8.13) and vitamin D analogues (2 trials; 51 patients; WMD, 3.73; 95% CI, 2.71 to 4.75), but not calcitonin (1 trial; 31 patients; WMD, -0.30; 95% CI, -5.00 to 4.40), had a favorable effect on BMD measured at the femoral neck compared with no treatment. The incidence of reported toxicity was low. CONCLUSION:
|
Authors | Suetonia C Palmer, Giovanni F M Strippoli, David O McGregor |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 45
Issue 4
Pg. 638-49
(Apr 2005)
ISSN: 1523-6838 [Electronic] United States |
PMID | 15806466
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Diphosphonates
- Immunosuppressive Agents
- Selective Estrogen Receptor Modulators
- Steroids
- Vitamin D
- Calcitonin
- Fluorides
- Calcium
|
Topics |
- Bone Density
(drug effects)
- Calcitonin
(therapeutic use)
- Calcium
(therapeutic use)
- Chronic Kidney Disease-Mineral and Bone Disorder
(etiology)
- Diphosphonates
(therapeutic use)
- Female
- Femur Neck
(chemistry)
- Fluorides
(therapeutic use)
- Fractures, Spontaneous
(epidemiology, etiology, prevention & control)
- Hormone Replacement Therapy
- Humans
- Immunosuppressive Agents
(adverse effects)
- Kidney Failure, Chronic
(complications, surgery)
- Kidney Transplantation
- Lumbar Vertebrae
(chemistry)
- Male
- Osteoporosis
(epidemiology, etiology, prevention & control)
- Osteoporosis, Postmenopausal
(drug therapy)
- Postoperative Complications
(prevention & control)
- Randomized Controlled Trials as Topic
(statistics & numerical data)
- Risk
- Selective Estrogen Receptor Modulators
(therapeutic use)
- Steroids
(therapeutic use)
- Treatment Outcome
- Vitamin D
(analogs & derivatives, therapeutic use)
|